Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/3/2025 | $16.00 | Equal-Weight | Morgan Stanley |
| 5/8/2025 | $14.00 | Equal Weight → Overweight | Barclays |
| 2/27/2025 | $16.00 | Buy | TD Cowen |
| 9/27/2024 | $16.00 | Neutral → Buy | UBS |
| 4/10/2024 | $23.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 4/4/2024 | Mkt Perform | JMP Securities | |
| 2/26/2024 | $19.00 | Market Perform | Leerink Partners |
| 12/7/2023 | $17.00 | Neutral | UBS |
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
4 - Certara, Inc. (0001827090) (Issuer)
Morgan Stanley resumed coverage of Certara with a rating of Equal-Weight and set a new price target of $16.00
Barclays upgraded Certara from Equal Weight to Overweight and set a new price target of $14.00
TD Cowen initiated coverage of Certara with a rating of Buy and set a new price target of $16.00
SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)
10-Q - Certara, Inc. (0001827090) (Filer)
8-K - Certara, Inc. (0001827090) (Filer)
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue was $57.9 million, compared to $55.1 million in the second quarter of 2024, representing growth of 5%. Net loss was $2.0 million, compared to a net loss of $12.6 million in the second quarter of 2024, repr
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA qualification for a PBPK modeling platform, and Simcyp is the only software to hold this designation. The recognition follows a rigorous multi-year, collaborative engagement between Certara and the EMA. With this qualification in place, sponsors can now use the Simcyp Simulator in regulatory submissions across the EU to assess drug-drug interaction (DDI) risk without needing to re-establish the platform
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data
SC 13G - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
SC 13G/A - Certara, Inc. (0001827090) (Subject)
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 million, compared to $93.3 million in the second quarter of 2024, representing growth of 12%. Software revenue was $46.7 million, compared to $38.2 million in the second quarter of 2024, representing growth of 22%.Service revenue was $57.9 million, compared to $55.1 million in the second quarter of 2024, representing growth of 5%. Net loss was $2.0 million, compared to a net loss of $12.6 million in the second quarter of 2024, repr
RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using b
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue was $59.6 million, flat compared to $57.3 million in the first quarter of 2024, representing growth of 4%. Net income was $4.7 million, a $9.4 million increase compared to a net loss of $4.7 million in t
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&